PMV Pharmaceuticals published Phase I results of rezatapopt in the New England Journal of Medicine, reporting objective responses in heavily pretreated patients whose tumors harbored the TP53 Y220C mutation. The oral p53‑reactivator was generally well tolerated across dose‑escalation cohorts and produced pharmacodynamic and biomarker signals consistent with selective Y220C pocket binding and restoration of p53 function. The trial enrolled 77 patients across tumor types; all responders were TP53 Y220C‑mutant and KRAS wild‑type. PMV outlined plans to pursue registrational Phase II strategy with a targeted NDA submission in platinum‑resistant/refractory ovarian cancer in early 2027. Scientific context: Allele‑selective small molecules that restore mutant p53 function have been a long‑sought strategy; this data represents proof‑of‑concept for targeting a defined structural pocket in TP53 and may catalyze mutation‑directed development programs.